We evaluate unique clinical and drug development challenges in biochemically recurrent (BCR) prostate cancer. We examine risk stratification, critically appraise trials, and outline ongoing and future development of hormonal and non-hormonal options.

Biographies:

Lauren O'Loughlin, MD, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA